The biotech IPO queue has added two more companies. Freeline Therapeutics and Checkmate Pharmaceuticals have each filed the regulatory paperwork to offer shares to the public.

Freeline is raising cash to ensure that its lead program, a prospective hemophilia B gene therapy, keeps pace in the race to develop and commercialize a genetic treatment for the inherited blood clotting disorder.

In paperwork filed with securities regulators late last week, Stevenage, UK-based Freeline set a preliminary $100 million target for its IPO, through which it plans to offer American depositoInterry shares on the Nasdaq. The company says in its filing that it… Read more »